



ASX ANNOUNCEMENT

10 March 2017

Proactive Investor Conference Presentation

Please find enclosed an Investor Presentation, which Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), will be presenting at the *Proactive's CEO Spotlight Investor Session*.

Cynata Managing Director and Chief Executive Officer Dr Ross Macdonald will be presenting at the event in Sydney and Melbourne on the following dates.

Sydney – Tuesday, 14th March 2017 from 12-noon to 2.30pm

Radisson Blu Hotel, Marble Room (Cnr. Pitt and O'Connell Street, Sydney)

Melbourne – Wednesday, 15th March 2017 from 12-noon to 2.30pm

CQ Functions, Events Room 1 (113 Queen Street, Melbourne)

For more information and to register your interest in attending please go to:

<http://www.proactiveinvestors.com.au/events>

The Presentation will focus on the Company's leading Cymerus™ technology that utilises induced pluripotent stem cells (iPSCs) from just one donor in a one-time donation to produce and manufacture mesenchymal stem cells (MSCs) for therapeutic use. The presentation will cover the benefits of this technology, the medical conditions that it seeks to address and the significant market opportunity.

The Company will also discuss its strategic alliance with FUJIFILM, a global leader in regenerative medicine, to develop and commercialise Cynata's technology, including its first Cymerus MSC product, CYP-001 which is poised to begin a world-first clinical trial.

Ends

CONTACTS: Dr Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com
Andrew Ramadge, Australia Media Contact, 0475 797 471, andrew.ramadge@mcpartners.com.au

cynata
therapeutics



A Next Generation Stem Cell Company

Dr. Ross Macdonald, CEO
Cynata Therapeutics Limited

Proactive Investor Lunch, March 2017

Important Information

This presentation has been prepared by Cynata Therapeutics Limited. (“Cynata” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Cynata Therapeutics, nor does it constitute financial product advice or take into account any individual’s investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Cynata Therapeutics and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Cynata Therapeutics is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Cynata Therapeutics securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Cynata Therapeutics, its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Cynata Therapeutics does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

The distribution of this presentation may be restricted by law and you should observe any such restrictions.

Forward looking statements

This presentation contains certain forward looking statements that are based on the Company’s management’s beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Cynata to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the political and economic environment in which Cynata will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Cynata and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

Key Facts

Cynata Therapeutics Ltd is an Australian stem cell and regenerative medicine company.



ASX CODE
CYP



COMMENCED OPERATIONS
November 2013



MARKET CAP (10 March 17)
A\$ 44m



SHARES ON ISSUE
90m¹



CASH
\$ 3.9m as at 31 Dec 2016
\$10m raised in Jan 2017 via placement and Fujifilm strategic partnership



AVERAGE MONTHLY NET CASH BURN
A\$470k (gross)



NUMBER OF SHAREHOLDERS
~1900; FUJIFILM ~9%

¹ Plus 10.8m Options: 3.7m Jul 20 @ AUD \$1.00; plus 5m 27 Sep 18 unlisted AUD \$0.40 restricted options, 50% to each of S Washer and R Macdonald


Why Invest in Cynata?

Competitive Strengths

- ▶ Disruptive platform technology, Cymerus™ facilitates the manufacture of allogeneic mesenchymal stem cells at scale
- ▶ Partnership with FUJIFILM: global leader in regenerative medicine
- ▶ World-first Phase 1 clinical trial
- ▶ Near term value catalysts
- ▶ Low development risk
- ▶ Stem cell market expected to be worth US\$170 billion by 2020¹
- ▶ Strong IP cover
- ▶ Strong balance sheet
- ▶ Experienced team
- ▶ Ethically non-controversial

Source: 1. Grand View Research Report published Sept 2015
<http://www.grandviewresearch.com/industry-analysis/stem-cells-market>

Cynata Milestones



Strong Partnerships

FUJIFILM

A major multinational with businesses in healthcare, graphic systems, functional materials, optical devices, digital imaging and document products

- Definitive option agreement to an exclusive, worldwide licence to market and sell CYP-001 for graft-versus-host disease (GvHD)
- Strategic acquisition of CYP shares: AUD\$3.97m @ 35% premium to 6 month VWAP
- Upfront + milestone payments + double-digit royalties on product sales
- GvHD peak sales potential of US\$300m¹
- Significant and growing business in regenerative medicine: acquired Cellular Dynamics International, Inc in 2015 for \$US307m (nearly 10x Cynata's market cap)
- Group revenue in 2015-2016: \$US22bn; 79,000 employees; market cap ~\$US21b

Academic Partnerships



University of Wisconsin
Core Cymerus technology



Harvard/MGH
Use of modified MSCs in cancer.



University of Massachusetts
GvHD model



University of Sydney
heart disease study



MONASH University
Monash University
Asthma study

About Cynata's Technology



(animation)

Why Are Stem Cells Important?

- Stem cells are important because of their potential to regenerate and repair damaged tissue
- Stem cells as therapies for disease have attracted significant media interest and medical research for a wide range of diseases
- Mesenchymal Stem Cells (MSCs) are specialised stem cells that can be used as therapeutics.
- MSCs play a key role in modulating inflammation and co-ordinating repair



Multiple sclerosis: Stem cell transplantation may halt disease progression

New research provides further evidence of autologous hematopoietic stem cell transplantation as an effective treatment for multiple sclerosis, after finding the procedure halted disease progression for 5 years in almost half of patients.

THE HUFFINGTON POST

Why People Are Traveling For Stem Cell Treatment

03/24/2017 01:58 pm ET | Updated Feb 24, 2017

ScienceDaily

Synthetic stem cells could offer therapeutic benefits, reduced risks

Date: December 26, 2016

Source: North Carolina State University

Summary: Researchers have developed a synthetic version of a cardiac stem cell. These synthetic stem cells offer therapeutic benefits comparable to those from natural stem cells and could reduce some of the risks associated with stem cell therapies. Additionally, these cells have better preservation stability and the technology is generalizable to other types of stem cells.

Daily Telegraph




Stem cell research gives new hope for treating heart failure, heart disease, diabetes and Parkinson's

Mesenchymal Stem Cell (MSC) Therapeutics

~652* open clinical studies using MSCs including:








Annual Market Value (\$US)



- Profound legislative changes to expedite stem cell therapies (Japan)
- Massive government investment e.g. California (CIRM): US\$3bn
- Significant potential applications including spinal cord injuries, stroke, Alzheimer's disease, Parkinson's disease, diabetes, heart attack

1. US Centre for Disease Control and Prevention
2. GBI Research
3. GBI Research
4. BCC Research
5. Research and Markets
*www.clinicaltrials.gov

Cynata's Therapeutic Product Pipeline

Therapeutic Area	Indication	Preclinical	Phase 1	Phase 2
Immunological Disorders	Graft versus host disease			
	Organ transplant rejection			
Pulmonary Disorders	Pulmonary fibrosis			
	Asthma			
Circulatory Disorders	Critical limb ischaemia			
	Myocardial infarction (heart attack)			
Cancer	Glioblastoma (brain tumour)			



Graft vs Host Disease

What

Potentially fatal complication that can occur after a bone marrow transplant in cancer patients when the donor's immune cells attack the host (patient).

Market

Global GvHD market value estimated to increase from US\$295m in 2013 to US\$544m in 2023 ¹.

Why

Cynata has targeted GvHD in a Phase 1 clinical trial.

Speedy results with efficacy in GvHD:

→ further potential indications

¹ E.Vouvatsikou, 2015, Global Data

Current Challenge for MSC Medicines: Manufacture




Cynata's Cymerus™ platform overcomes the inherent challenges facing the manufacture of mesenchymal cells (MSCs) at scale


The Solution: Cynata's Cymerus™ Platform

An innovative and efficient production process that enables commercial-scale manufacture of a consistent, robust and premier grade MSC product:

...*better, cheaper, faster*



Cynata's Cymerus™ : Outstanding Pedigree



Inventors include: Dr James Thomson

- In 1998 derived the first human embryonic stem cell line
- 2007 derived human induced pluripotent stem cells



...and Prof Igor Slukvin, co-founder and author of >70 publications in the stem cell field



In-licensed intellectual property includes several issued U.S. patents as well as a broad estate of issued and pending patents

BUSINESS MODEL: Commercial Partnerships

Capital efficient license-driven strategy

Revenue Streams

- License payments

Licensing Cymerus™ platform to big pharma/biotech

- Milestone payments

From partners as products progress

- Royalties

From partner revenue of marketed products

Already secured commercial agreements with global cell and regenerative medicine companies

FUJIFILM

- Definitive agreement: equity, upfronts, milestones and royalties
- Strategic investor; brings substantial resources

apceth[®]
applied cell therapy

- License option agreement
- Upfronts, milestones and royalties
- Opens new commercial opportunities for modified MSCs

High Activity Pipeline

What's Next?

Commence WORLD-FIRST Phase 1 trial;
Formal interaction with FDA

Licence option agreement with apceth

Additional commercial + development
partnerships

Continued success of MSC-based therapeutics



Investment Highlights **Summary**

- **Only company** in the world that can mass-produce therapeutic stem cells at a consistent quality and affordable cost
- Cynata's Cymerus™ technology **overcomes the challenges inherent in first generation production** methods and the regulatory hurdles by industrialising the production of mesenchymal stem cells (MSCs)
- **Strong data in pre-clinical studies** for the treatment of asthma, heart attack, GvHD (Graft-versus-Host disease) and critical limb ischaemia
- **Regenerative medicine market expected to grow to US\$170bn** by 2020 and an attractive investment area for biopharmaceutical companies, including Astellas, J&J and Fujifilm
- **Licensing-driven business model with near term revenue** and commercial partnerships in place with Fujifilm and apceth GmbH & Co KG
- **Experienced management** team and strong academic partnerships
- **Value-accretive news flow** expected in near term

Thank you for your attention

Cynata Therapeutics Limited
Suite 1,
1233 High Street,
Armadale, Victoria 3143



Contact details:

✉ ross.macdonald@cynata.com

☎ +61 (0) 412 119343

🌐 www.cynata.com

